Observational studyMedicine2025
Analysis of factors influencing lung cancer in patients with type 2 diabetes mellitus.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study examined factors influencing lung cancer in patients with type 2 diabetes mellitus (T2DM). A total of 111 patients with T2DM diagnosed with stage IIIB or IV lung cancer and treated at Jining No. 1 People's Hospital between January 2015 and December 2020 were included. Diagnoses were confirmed through bronchoscopy and/or percutaneous biopsy under computed tomography guidance. Patient age, sex, pathological type, treatment, and progression-free survival (PFS) were recorded. Survival analysis and Cox proportional hazards model multifactor analysis were performed using the Kaplan-Meier method to identify factors influencing survival. Univariate analysis revealed the following: (1) PFS was significantly longer in women than in men (12.50 vs 8.63 months, relative risk [RR] = 0.76, 95% confidence interval [CI] = 0.45-1.28, P = .042), (2) PFS differed significantly among patients with adenocarcinoma, squamous cell carcinoma, and small cell lung cancer (12.29 vs 10.02 vs 7.12 months, RR = 1.5, 95% CI = 1.07-2.0, P = .027). Compared with small cell lung cancer, PFS was significantly longer in adenocarcinoma (12.29 vs 7.12 months, P = .011), (3) PFS varied across chemotherapy, tyrosine kinase inhibitor therapy, and chemoradiotherapy (6.69 vs 14.50 vs 13.97 months, RR = 0.86, 95% CI = 0.74-0.99, P = .001). Compared with chemotherapy, PFS was significantly longer in patients receiving targeted therapy and chemoradiotherapy (14.50 vs 6.69 months, P = .001; 13.97 vs 6.69 months, P = .008), and (4) No significant difference in PFS was observed between patients who received metformin therapy and those who did not (9.96 vs 9.95 months, P = .926). In multivariate analysis, pathological type and treatment modality were identified as independent factors influencing PFS in patients with advanced lung cancer and T2DM (P < .05). In patients with advanced lung cancer and T2DM, PFS was significantly longer in women, particularly those with adenocarcinoma and those treated with epidermal growth factor receptor-tyrosine kinase inhibitors or chemoradiotherapy. Pathological type and treatment were independent factors influencing PFS in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.